167 phenotypes from 7 alleles in 10 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Cyp19a1tm1.1Shah/Cyp19a1tm1.1Shah involves: 129S/SvEv * C57BL/6	no abnormal phenotype detected	J:156012
Cyp19a1tm1b(EUCOMM)Hmgu/Cyp19a1tm1b(EUCOMM)Hmgu C57BL/6N-Cyp19a1tm1b(EUCOMM)Hmgu/H	abnormal gait	J:211773
	decreased circulating alkaline phosphatase level	J:211773
	decreased exploration in new environment	J:211773
	decreased lean body mass	J:211773
	decreased leukocyte cell number	J:211773
	decreased locomotor activity	J:211773
	decreased lymphocyte cell number	J:211773
	decreased mean corpuscular hemoglobin concentration	J:211773
	increased anxiety-related response	J:211773
	increased blood urea nitrogen level	J:211773
	increased circulating cholesterol level	J:211773
	increased circulating serum albumin level	J:211773
	increased fasting circulating glucose level	J:211773
	increased neutrophil cell number	J:211773
	increased total body fat amount	J:211773
	thrombocytosis	J:211773
	tremors	J:211773
Cyp19a1tm1Esi/Cyp19a1tm1Esi involves: 129S6/SvEvTac	abnormal auditory brainstem response	J:135833
	abnormal glucose homeostasis	J:65805
	abnormal mating frequency	J:83254
	abnormal mature ovarian follicle morphology	J:78634
	abnormal ovary morphology	J:78634
	abnormal primary sex determination	J:78634
	abnormal spermatogenesis	J:83254
	abnormal tertiary ovarian follicle morphology	J:78634
	absent corpus luteum	J:78634
	asthenozoospermia	J:83254
	bradykinesia	J:65805
	decreased lean body mass	J:65805
	enlarged liver	J:65805
	hepatic steatosis	J:65805
	impaired ovarian folliculogenesis	J:78634
	increased body weight	J:65805
	increased circulating cholesterol level	J:65805
	increased circulating HDL cholesterol level	J:65805
	increased circulating insulin level	J:65805
	increased circulating leptin level	J:65805
	increased circulating triglyceride level	J:65805
	increased fat cell size	J:65805
	increased gonadal fat pad weight	J:65805
	increased renal fat pad weight	J:65805
	increased total body fat amount	J:65805
	oligozoospermia	J:83254
	ovary cyst	J:78634
	ovary hemorrhage	J:78634
	pale liver	J:65805
	reduced male fertility	J:83254
	reduced male mating frequency	J:83254
Cyp19a1tm1Esi/Cyp19a1tm1Esi involves: 129S6/SvEvTac * C57BL/6	abnormal acrosome assembly	J:56358
	abnormal baroreceptor physiology	J:105620
	abnormal coat/hair pigmentation	J:48086
	abnormal enzyme/coenzyme level	J:105620
	abnormal epididymis morphology	J:56358
	abnormal labium morphology	J:48086
	abnormal male germ cell morphology	J:56358
	abnormal male reproductive system morphology	J:48086
	abnormal ovary morphology	J:48086, J:63458
	abnormal prostate gland physiology	J:70204
	abnormal reproductive system physiology	J:48086
	abnormal salivary gland morphology	J:92438
	abnormal seminiferous tubule epithelium morphology	J:56358
	abnormal seminiferous tubule morphology	J:56358
	abnormal spermatid morphology	J:56358
	abnormal spermatogenesis	J:56358
	abnormal spermiogenesis	J:56358
	abnormal spleen germinal center morphology	J:92438
	abnormal systemic arterial blood pressure	J:105620
	abnormal uterus development	J:63458
	absent corpus luteum	J:48086, J:63458
	anovulation	J:63458
	arrest of spermiogenesis	J:56358
	decreased heart rate variability	J:105620
	decreased male germ cell number	J:56358
	decreased mean systemic arterial blood pressure	J:105620
	decreased systemic arterial diastolic blood pressure	J:105620
	decreased testis weight	J:56358
	decreased uterus weight	J:63458
	enlarged clitoris	J:48086
	enlarged mesenteric lymph nodes	J:92438
	enlarged prostate gland	J:70204
	enlarged salivary gland	J:92438
	enlarged spleen	J:92438
	female infertility	J:48086, J:63458
	impaired ovarian folliculogenesis	J:48086, J:63458
	increased autoantibody level	J:92438
	increased B cell number	J:92438
	increased bone marrow cell number	J:92438
	increased cardiac muscle contractility	J:105620
	increased circulating dihydrotestosterone level	J:70204
	increased circulating follicle stimulating hormone level	J:48086, J:56358, J:63458
	increased circulating luteinizing hormone level	J:48086, J:56358, J:63458
	increased circulating prolactin level	J:70204
	increased circulating testosterone level	J:48086, J:56358, J:70204
	increased gonadal fat pad weight	J:48086
	increased granulocyte number	J:92438
	increased granulosa cell apoptosis	J:63458
	increased heart rate	J:105620
	increased IgG level	J:92438
	increased leukocyte cell number	J:92438
	increased Leydig cell number	J:56358
	increased lymphocyte cell number	J:92438
	increased male germ cell apoptosis	J:56358
	increased mammary fat pad weight	J:48086
	increased mature B cell number	J:92438
	increased prostate gland anterior lobe weight	J:70204
	increased prostate gland dorsolateral lobe weight	J:70204
	increased prostate gland ventral lobe weight	J:70204
	increased prostate gland weight	J:48086, J:70204
	increased seminal vesicle weight	J:48086
	increased urine protein level	J:92438
	kidney inflammation	J:92438
	male infertility	J:56358
multinucleated giant male germ cells	J:56358
obese	J:92438
ovarian follicular cyst	J:63458
ovary hemorrhage	J:63458
prostate gland anterior lobe hyperplasia	J:70204
prostate gland dorsolateral lobe hyperplasia	J:70204
prostate gland hyperplasia	J:70204
prostate gland ventral lobe hyperplasia	J:70204
renal glomerular immunoglobulin deposits	J:92438
salivary gland inflammation	J:92438
spleen hyperplasia	J:92438
uterus hypoplasia	J:48086
Cyp19a1tm1Esi/Cyp19a1tm1Esi involves: 129S6/SvEvTac * C57BL/6J	abnormal barbering behavior	J:129528
	abnormal emotion/affect behavior	J:129528
	abnormal locomotor activation	J:129528
	abnormal short-term spatial reference memory	J:89632
	increased grooming behavior	J:129528
Cyp19a1tm1Sih/Cyp19a1tm1Sih involves: 129S/SvEv	abnormal ovary morphology	J:51076
	abnormal salivary gland morphology	J:216958
	abnormal uterus development	J:51076
	abnormal white adipose tissue morphology	J:216958
	absent corpus luteum	J:51076
	decreased uterus weight	J:51076
	female infertility	J:51076
	increased abdominal adipose tissue amount	J:216958
	increased aggression towards female mice	J:51076
	increased anti-single stranded DNA antibody level	J:216958
	increased autoantibody level	J:216958
	increased dendritic cell number	J:216958
	increased macrophage cell number	J:216958
	increased susceptibility to autoimmune disorder	J:216958
	increased total body fat amount	J:51076
	lacrimal gland inflammation	J:216958
	reduced male fertility	J:51076
	reduced male mating frequency	J:51076
	salivary gland inflammation	J:216958
Cyp19a1tm1Sih/Cyp19a1tm1Sih involves: 129S/SvEv * C57BL/6	abnormal copulation	J:84396
	abnormal parental behavior	J:84396
	abnormal sexual interaction	J:84396
	decreased aggression towards male mice	J:84396
	failure of ejaculation	J:84396
	increased aggression towards female mice	J:84396
	male infertility	J:84396
	reduced male fertility	J:84396
	reduced male mating frequency	J:84396
Cyp19a1tm1Toda/Cyp19a1tm1Toda involves: 129P2/OlaHsd * C57BL/6J	abnormal bone trabecula morphology	J:114305
	abnormal compact bone morphology	J:114305
	abnormal enzyme/coenzyme level	J:79603
	abnormal lipid homeostasis	J:79603
	abnormal liver lobule morphology	J:79603
	abnormal liver physiology	J:79603
	abnormal ovary morphology	J:70359
	abnormal seminiferous tubule epithelium morphology	J:68190
	abnormal sexual interaction	J:68190
	abnormal trabecular bone morphology	J:114305
	absent corpus luteum	J:70359
	absent ovarian follicles	J:70359
	anovulation	J:70359
	decreased bone mass	J:114305
	decreased bone mineral density of femur	J:114305
	decreased circulating estradiol level	J:70359, J:114305
	decreased uterus weight	J:70359, J:114305
	failure of superovulation	J:70359
	female infertility	J:68190, J:70359
	hepatic steatosis	J:79603, J:82070
	impaired glucose tolerance	J:82070
	impaired luteinization	J:70359
	increased abdominal fat pad weight	J:79603, J:82070
	increased body weight	J:82070
	increased bone resorption	J:114305
	increased circulating cholesterol level	J:82070
	increased circulating glucose level	J:82070
	increased circulating testosterone level	J:68190, J:70359, J:82070, J:114305
	increased circulating triglyceride level	J:82070
	increased gonadal fat pad weight	J:82070
	increased osteoclast cell number	J:114305
	increased ovary apoptosis	J:70359
	increased renal fat pad weight	J:82070
	increased seminal vesicle weight	J:114305
	increased susceptibility to weight gain	J:82070
	insulin resistance	J:82070
	obese	J:82070
	ovary cyst	J:70359
	ovary hemorrhage	J:70359
	reduced male fertility	J:68190
	small uterus	J:70359
	thin endometrium	J:70359
	thin myometrium	J:70359
Cyp19a1tm1Toda/Cyp19a1tm1Toda Not Specified	decreased aggression	J:68373
Cyp19a1tm2.1(cre)Shah/Cyp19a1tm2.1(cre)Shah B6.129S(SJL)-Cyp19a1tm2.1(cre)Shah	normal homeostasis/metabolism phenotype	J:220075
	normal reproductive system phenotype	J:220075
Tg(Cyp19)C2-3Rrte/0 involves: BALB/c * C57BL/6	enlarged testis	J:60034
	increased circulating estradiol level	J:60034
	increased fibroadenoma incidence	J:34063
	increased incidence of tumors by chemical induction	J:69745
	increased mammary gland tumor incidence	J:78693
	male infertility	J:60034
	mammary gland duct hyperplasia	J:34063
	mammary gland hyperplasia	J:34063, J:78693